Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
AS-703026
As low as
CHF 85.00
In stock
Only %1 left
SYN-1190-M0011 mgCHF 85.00
SYN-1190-M0055 mgCHF 128.00
SYN-1190-M01010 mgCHF 170.00
SYN-1190-M05050 mgCHF 553.00
SYN-1190-M100100 mgCHF 922.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | AS703026 |
| Product Type | Chemical |
| Properties | |
| Formula | C15H15FIN3O3 |
| MW | 431.2 |
| CAS | 1236699-92-5 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: MEK1 - MEK2 | Kinase Group: STE | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | VIUAUNHCRHHYNE-JTQLQIEISA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Use/Stability | Stable for at least 1 year after receipt when stored at +4°C. |
| Documents | |
| Safety Data Sheet |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
AS703026 is a novel, selective, non-competitive, orally bioavailable MEK1/2 inhibitor with experimental IC(50) values of 5-11nM. In use on multiple myeloma cells (MM), AS703026 inhibited growth and survival of MM cells and cytokine-induced osteoclast differentiation more potently (~10X) than AZD6244. Inhibition of proliferation induced by AS703026 was mediated by G0-G1 cell cycle arrest and was accompanied by reduction of MAF oncogene expression. AS703026 further induced apoptosis via caspase 3 and Poly ADP ribose polymerase (PARP) cleavage in MM cells, both in the presence or absence of bone marrow stromal cells (BMSCs). Importantly, AS703026 sensitized MM cells to a broad spectrum of conventional (dexamethasone, melphalan), novel or emerging (lenalidomide, perifosine, bortezomib, rapamycin) anti-MM therapies. Significant tumour growth reduction in AS703026- vs. vehicle-treated mice bearing H929 MM xenograft tumours correlated with downregulated pERK1/2, induced PARP cleavage, and decreased microvessels in vivo. Moreover, AS703026 (< 200nM) was cytotoxic against the majority of tumour cells tested from patients with relapsed and refractory MM (84%), regardless of mutational status of RAS and BRAF genes. Importantly, BMSC-induced viability of MM patient cells was similarly blocked within the same dose range.
Product-specific References
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo: K. Kim, et al.; Br. J. Haematol. 149, 537 (2010)
- MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy: J. Yoon, et al.; J. Cancer Res. 71, 445 (2011)
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF